Australia is becoming an increasingly important destination for clinical research, particularly for Phase I, early-phase, oncology, rare disease, metabolic, radiopharmaceutical, cell and gene therapy, and first-in-human studies.

The opportunity is not limited to conducting clinical trials. Sponsors increasingly need faster site activation, patient recruitment, regulatory coordination, clinical data management, real-world evidence, biostatistics, medical writing, and cross-border development support.

According to Towards Healthcare, the Australia clinical research services market was valued at USD 2.00 billion in 2025 and is projected to reach USD 4.87 billion by 2035, expanding at a 9.3% CAGR from 2026 to 2035. The market is estimated at USD 2.19 billion in 2026.

Australia’s underlying clinical-trial ecosystem also has substantial scale. MTPConnect reported approximately 1,850 trials commenced and 90,000 Australians participating in clinical trials in 2022, while clinical-trial expenditure reached USD 1.6 billion equivalent in Australian dollars.

The commercial question for pharmaceutical companies, biotechnology companies, CROs, investors, and healthcare service providers is therefore no longer whether Australia is relevant.

It is:

Where are the strongest clinical research opportunities, who is buying these services, what capabilities are in demand, and which companies are best positioned to capture the growth?

Australia Clinical Research Services Market Size at a Glance

Metric	Australia
Market size, 2025	USD 2.00 billion
Market size, 2026	USD 2.19 billion
Forecast, 2035	USD 4.87 billion
CAGR, 2026–2035	9.3%
Clinical trial expenditure, 2022	~AUD 1.6 billion
Clinical trials commenced, 2022	~1,850
Trial participants, 2022	~90,000
Clinical trial support services, 2025	USD 594.5 million
Patient recruitment services, 2025	USD 264.7 million

Source: Towards Healthcare;

Why Is Australia’s Clinical Research Services Market Growing?

Several factors are strengthening Australia’s position.

Strong healthcare infrastructure

Australia combines a developed healthcare system, experienced investigators, university hospitals, specialist research institutes, and established clinical-trial networks.

This makes the country attractive to international sponsors that want to generate clinical evidence in a regulated environment before expanding into other markets.

Early-phase clinical development

Australia has particular relevance for Phase I and first-in-human studies.

Towards Healthcare estimates that Phase I represented around 14% of market revenue in 2025 and is expected to be the fastest-growing phase segment, with an estimated 11.5% CAGR through 2035.

For biotechnology companies with limited time and funding, the ability to move from protocol development to first-patient dosing quickly can be commercially important.

Foreign sponsor interest

International biotechnology and pharmaceutical companies are increasingly using Australia as an entry point into Asia-Pacific clinical development.

For example, Novotech supported a U.S. biotechnology company in launching first-in-human mRNA oncology trials in Australia before expanding into South Korea and Taiwan. The program activated six Australian sites and achieved 24 of 32 planned Australian enrollments.

This demonstrates a broader strategic model:

Australia can serve as the first clinical-development market before sponsors expand across APAC.

Australia Clinical Research Services TAM, SAM and SOM

A conventional TAM/SAM/SOM framework is useful for understanding where commercial opportunities sit inside the broader ecosystem.

However, clinical research services do not have a single government-defined TAM/SAM/SOM dataset. Therefore, the following framework uses the Towards Healthcare 2025 service-layer model, rather than presenting the figures as government statistics.

TAM – USD 3.26 Billion

Towards Healthcare estimates Australia’s broader healthcare CRO opportunity at approximately USD 3.26 billion in 2025.

This represents the broader addressable CRO environment covering clinical and related outsourced research activities.

SAM – USD 594.5 Million

The clinical trial support services opportunity was approximately USD 594.5 million in 2025.

This includes services supporting trial execution across areas such as site management, patient recruitment, data management, and other clinical-trial activities. Grand View Research independently estimates the Australian clinical-trial support services segment at the same USD 594.5 million level for 2025.

Priority SOM Opportunity – USD 264.7 Million

Patient recruitment represented approximately USD 264.7 million in 2025, making it one of the most commercially important specialized opportunities within clinical trial support services.

Rather than treating this as a literal guaranteed SOM for one company, it is more useful to consider the figure a priority addressable service wedge.

For a CRO, technology company, recruitment platform, site network, or specialist provider, the commercial opportunity depends on its capabilities, geographic coverage, therapeutic focus, and sponsor relationships.

What Does the TAM–SAM–SOM Structure Mean for Investors?

The structure reveals three different levels of opportunity.

TAM: Broad CRO and outsourced clinical development opportunity.

SAM: Clinical trial support activities that can be directly outsourced.

Priority opportunity: Recruitment and other specialized services where sponsors face measurable execution challenges.

This distinction is important because simply competing as a full-service CRO is not the only growth strategy.

Companies can specialize in:

• Patient recruitment
• Site feasibility
• Phase I trials
• Oncology trials
• Rare disease trials
• Radiopharmaceutical studies
• Clinical data management
• Biostatistics
• Regulatory consulting
• Real-world evidence
• Decentralized trials
• Medical writing
• Pharmacovigilance
• Clinical supply management

Clinical Trial Volume Shows the Depth of the Opportunity

Australia’s clinical research ecosystem has significant trial volume.

MTPConnect reported around 1,850 clinical trials commenced in 2022, with approximately 90,000 Australians participating. The sector employed approximately 7,700 people and generated around AUD 1.6 billion in expenditure.

The longer-term trend is also important.

MTPConnect’s earlier analysis found approximately 1,880 trials commenced in 2019, involving around 95,000 participants and more than 8,000 workers.

Although overall trial volume was relatively stable between 2019 and 2022, commercially sponsored trials increased from 619 to 646, while Phase I activity maintained strong long-term growth.

This suggests that the opportunity is increasingly being driven by quality, complexity, outsourcing, and commercial sponsorship rather than simply the number of studies.

Which Clinical Trial Phases Generate the Most Value?

Towards Healthcare estimates that Phase III accounted for approximately 41% of market revenue in 2025, while another TH analysis places the Phase III revenue contribution at approximately 56.73% depending on market definition.

Phase III studies generally require:

• Larger patient populations
• More sites
• Greater monitoring requirements
• More complex data management
• Longer study durations
• Stronger regulatory coordination
• More extensive safety reporting
• Higher operational expenditure

At the same time, Phase I is attracting strategic interest because biotech companies increasingly want to reach human proof-of-concept quickly.

This creates a two-speed opportunity:

Phase I drives acceleration and innovation.

Phase III drives scale and revenue intensity.

Buyer Intelligence: Who Is Actually Buying Clinical Research Services?

The most important buyers include:

Large pharmaceutical companies

Large pharmaceutical companies typically require global CROs or specialized providers for large Phase II and Phase III programs, patient recruitment, data management, pharmacovigilance, and regulatory operations.

Their priorities are usually:

• Global execution
• Consistent data quality
• Patient recruitment
• Regulatory compliance
• Cost control
• Timeline management
• Risk reduction

Biotechnology companies

Biotech companies represent a particularly important buyer group for Australia’s early-phase ecosystem.

Smaller sponsors often have limited internal clinical-development infrastructure.

They therefore need external partners that can provide:

• Protocol support
• Regulatory strategy
• Ethics submissions
• Site selection
• Investigator identification
• First-patient dosing
• Recruitment
• Clinical operations
• Data management

Speed is particularly important for venture-backed companies operating with milestone-driven funding.

Medical device companies

Medical device sponsors require clinical evidence for regulatory and commercial purposes.

The MTPConnect report estimates approximately 9% of industry-sponsored clinical-trial expenditure is associated with medical-device trials, with the remaining 91% related to drug trials.

Academic and research institutions

Universities, hospitals, medical research institutes, and investigator-led organizations remain important participants.

MTPConnect estimated that non-industry organizations spent approximately AUD 350 million on clinical trials in 2022, including funding through the Medical Research Future Fund and other sources.

Buyer Behaviour: What Are Sponsors Looking For?

The Australian buyer is increasingly moving away from simply asking:

“Which CRO can run my trial?”

The more relevant questions are:

• How quickly can the first site open?
• How quickly can the first patient be dosed?
• Can the CRO recruit difficult populations?
• Does it have therapeutic-area expertise?
• Can it support TGA and ethics requirements?
• Can Australia serve as the first step into APAC?
• Can the same CRO coordinate multiple countries?
• Can the provider forecast recruitment accurately?
• Can it manage complex trial designs?
• Can it provide real-time operational visibility?

Novotech’s 2026 Australian oncology case illustrates this shift. In one Phase I/II study, the company reported ethics submission within one week of final protocol availability, approval in under seven weeks, first patient enrollment within one week of site activation, and 51 Australian patients enrolled against an original target of 30.

Speed, recruitment and operational execution are therefore becoming major buying criteria.

Consumer Behaviour: Patients and Clinical Trial Participants

Patients are not simply passive participants in the clinical research ecosystem.

Recruitment depends on:

• Awareness of available trials
• Trust in investigators and healthcare providers
• Trial accessibility
• Travel requirements
• Eligibility
• Time commitment
• Perceived benefit
• Financial reimbursement
• Communication quality

Scientia Clinical Research’s current recruitment activity illustrates the importance of participant economics in early-phase trials. Its Sydney-based studies advertise reimbursements ranging from approximately AUD 2,000 to AUD 15,000, depending on the study and participant commitment.

This creates a clear opportunity for recruitment platforms and CROs to improve participant engagement through:

• Digital recruitment
• Patient education
• Referral networks
• Multilingual communication
• Remote screening
• Better eligibility matching
• Site-level recruitment analytics

MTPConnect has also documented the economic value of improving trial referrals. Its ClinTrial Refer initiative produced a nine-fold increase in cross-referrals and a 63% increase in recruitment of urban and regional/rural patients across participating sites.

Leading Companies in Australia’s Clinical Research Ecosystem

Australia’s competitive environment includes global CROs, specialist Australian CROs, early-phase units, site networks, research institutes, and technology providers.

Novotech

Novotech is one of the most strategically important Australia-founded CROs.

Founded in Australia in 1997, Novotech moved its headquarters to Singapore in 2026 while maintaining a major APAC operating footprint. Dr. Anand Tharmaratnam became CEO and Chairman in January 2026. He previously spent 23 years at Quintiles and IQVIA, including 10 years on global executive committees.

Novotech’s current Australian activity includes oncology, mRNA, radiopharmaceutical, obesity, rare disease, and complex first-in-human programs.

Its recent work shows the growing importance of Australia as a launch point for APAC clinical development.

ICON

ICON maintains Australian entities providing clinical research services, including ICON Clinical Research Pty Ltd and Medpass International Pty Ltd.

The company’s presence demonstrates the continuing role of global CROs in Australia’s sponsor ecosystem.

Avance Clinical

Avance Clinical is strongly positioned around early-phase and clinical development services in Australia and New Zealand, particularly for international biotechnology sponsors.

Its positioning reflects one of Australia’s strongest competitive advantages: helping international sponsors use Australian trials to accelerate development and generate data suitable for international regulatory pathways.

Scientia Clinical Research

Scientia Clinical Research operates a purpose-built first-in-human Phase I unit in Sydney’s Randwick research hub.

Its current pipeline includes first-in-human and Phase I/II oncology programs involving bispecific antibodies, antibody-drug conjugates, and targeted therapies.

A recent Scientia development is particularly notable: the company reported completing dosing in January 2026 for ABS-1230 and subsequently treating the first patient globally in an ultra-rare KCNT1-related epilepsy program.

Recent Developments Shaping Australia’s Clinical Research Services Market

Australia is attracting increasingly complex trials

Australia is moving beyond traditional Phase I studies.

Current programs include:

• mRNA immunotherapies
• Cell therapies
• Radiopharmaceuticals
• Gene-modified therapies
• Precision oncology
• Rare disease therapies
• Obesity drugs
• Neurological therapies

Novotech’s 2026 case studies include first-in-human mRNA oncology trials and complex GMO oncology trials in Australia.

Radiopharmaceutical trials are expanding

Radiopharmaceutical development is becoming another strategic opportunity.

Novotech participated in Australia’s 2026 ARCS conference with a focus on operationalizing radiopharmaceutical trials, alongside Telix Pharmaceuticals and Australian clinical research stakeholders.

Rare disease development is gaining attention

The ABS-1230 program demonstrates how Australia’s early-phase infrastructure can support extremely small patient populations.

The study involved a disease for which only 18 Australians had historically been diagnosed, showing how specialist clinical research units can support highly targeted development programs.

Regulatory Environment and TGA Advantage

The Therapeutic Goods Administration is Australia’s principal regulator for therapeutic goods.

For sponsors, understanding Australia’s regulatory pathway is essential because clinical-trial execution involves interactions among sponsors, investigators, ethics committees, institutions, and regulatory authorities.

The TGA provides clinical-trial access pathways and regulatory guidance for medicines, biologicals, medical devices, and other therapeutic goods.

The regulatory environment becomes particularly important for:

• First-in-human studies
• Cell and gene therapies
• GMO trials
• Radiopharmaceuticals
• Novel biologics
• Combination products
• Rare disease therapies

Companies entering Australia therefore need more than a list of clinical sites. They need regulatory, operational, therapeutic-area, and commercial intelligence.

Import and Export Data: What Does Trade Tell Us?

Clinical research services are not reported by the Australian Bureau of Statistics as a single standalone customs product with a simple import-export code.

This matters because it is misleading to present a specific “clinical research services import volume” as if it were directly recorded in merchandise trade data.

Instead, the most appropriate public benchmark is Australia’s broader international trade in services.

In 2025, Australia exported AUD 142.1 billion in services, up 11.0%, while services imports reached AUD 179.5 billion, up 8.2%.

The United States was Australia’s second-largest services export partner at AUD 19.4 billion, while the U.S. was also Australia’s largest services import partner at AUD 46.0 billion.

This is relevant to clinical research because a significant portion of Australia’s clinical-trial activity is connected to foreign pharmaceutical and biotechnology sponsors bringing R&D investment into Australia.

MTPConnect previously identified clinical trials as an important source of services export revenue, noting that international industry sponsors contribute substantial foreign investment to Australia’s clinical-trial ecosystem.

What Should Buyers Track?

For commercial intelligence, the relevant cross-border indicators include:

• Foreign-sponsored trials
• CRO outsourcing contracts
• International sponsor activity
• Clinical supply imports
• Investigational medicinal product flows
• Laboratory services
• Data-management outsourcing
• Technology services
• Regulatory consulting
• Cross-border clinical development partnerships

These indicators provide a better picture of the international opportunity than traditional merchandise import-export statistics.

Volume Opportunity Across the Clinical Research Value Chain

The opportunity extends beyond CRO revenue.

A single clinical program can create demand across:

Sponsor → CRO → Site → Investigator → Patient → Laboratory → Data Management → Biostatistics → Regulatory → Clinical Supply → Pharmacovigilance → Medical Writing → Commercialization

Each stage creates potential revenue pools.

For example, a Phase III oncology study can require:

• Dozens of sites
• Hundreds of patients
• Central laboratory services
• Imaging
• Biomarker testing
• Monitoring
• Data management
• Statistical analysis
• Safety reporting
• Regulatory submissions
• Medical writing

Therefore, a rise in complex trials can generate significantly more outsourcing revenue even if the total number of trials does not rise proportionally.

Key Therapeutic Areas Driving Demand

Towards Healthcare identifies oncology as the largest therapeutic-area segment, representing approximately 26% of market revenue in 2025. Metabolic and endocrine disorders represented approximately 7% and were among the fastest-growing areas.

This aligns with Australia’s current clinical-development activity across:

• Oncology
• Obesity
• Diabetes
• Neurology
• Rare diseases
• Immunology
• Radiopharmaceuticals
• Cell and gene therapy

The combination of high disease burden and innovative pipelines makes these therapeutic areas particularly relevant for CROs and specialized service providers.

Major Challenges Buyers Face

Despite the opportunity, sponsors still face significant challenges.

Patient recruitment

Recruitment remains one of the largest operational risks.

Site availability

Complex therapies require specialized investigators and infrastructure, limiting the number of suitable sites.

Skilled workforce

MTPConnect has identified workforce shortages in clinical-trial operations and pharmaceutical manufacturing.

Trial complexity

Precision medicine, biomarkers, cell therapies, radiopharmaceuticals, and genetically modified therapies require more specialized operational capabilities.

Cost pressure

Sponsors need to balance Australia’s clinical quality with global development budgets.

APAC coordination

Sponsors increasingly want Australia to connect with other APAC countries, increasing the importance of cross-border regulatory and operational coordination.

What Clinical Research Buyers Should Evaluate Before Selecting a CRO

A buyer should evaluate more than company size.

1. Therapeutic expertise

Does the CRO have experience in the relevant disease and modality?

2. Recruitment capability

Can it demonstrate actual recruitment performance?

3. Site network

Does it have access to suitable investigators and high-performing sites?

4. Regulatory expertise

Can it manage TGA, ethics, biosafety, and other regulatory requirements?

5. Early-phase capabilities

Can it support FIH, Phase I, and dose-escalation programs?

6. APAC expansion

Can the provider extend an Australian study into South Korea, Japan, China, Taiwan, or other APAC markets?

7. Data quality

Can the provider maintain reliable data across complex multinational trials?

8. Timeline performance

Can it demonstrate measurable improvements in start-up and enrollment timelines?

Competitive Intelligence: Questions Companies Should Be Asking

Before entering or expanding in Australia, healthcare companies should answer:

• Which CROs are winning Australian sponsor contracts?
• Which CROs specialize in Phase I?
• Which companies dominate oncology trials?
• Which providers have the strongest patient-recruitment networks?
• Which sites have the highest trial activity?
• Which therapeutic areas are attracting international sponsors?
• Which companies are expanding their Australian infrastructure?
• Which CROs are expanding across APAC?
• Which companies are acquiring specialist clinical research providers?
• Which trial technologies are gaining adoption?
• Where are recruitment bottlenecks developing?
• Which government programs are supporting clinical research?

These questions turn public clinical-trial data into commercial intelligence.

How Towards Healthcare Research & Consulting Can Help

The Australian clinical research ecosystem is becoming more competitive, specialized, and international.

For pharmaceutical companies, biotechnology companies, CROs, investors, healthcare technology companies, and service providers, the challenge is not finding information.

The challenge is connecting the information to a business decision.

Towards Healthcare Research & Consulting can support organizations with:

TAM, SAM and SOM Analysis

Build market opportunity models that separate the total clinical research ecosystem from specific serviceable and priority revenue pools.

Buyer Intelligence

Identify pharmaceutical, biotech, medical-device, academic, and international sponsor requirements, buying priorities, outsourcing preferences, and unmet needs.

CRO Competitive Intelligence

Benchmark Novotech, ICON, Avance Clinical, Scientia, and other CROs across therapeutic expertise, trial phases, geographic presence, recruitment capabilities, partnerships, and expansion strategies.

Clinical Trial Intelligence

Track trials by:

• Sponsor
• Phase
• Therapeutic area
• Molecule
• Modality
• Investigator
• Site
• Patient population
• Trial status
• Geography

Patient Recruitment Intelligence

Assess recruitment challenges, patient availability, referral patterns, trial accessibility, and opportunities for digital recruitment.

Regulatory Intelligence

Track TGA developments, clinical-trial pathways, ethics requirements, regulatory changes, and implications for sponsors.

Import and Export Intelligence

Analyze relevant cross-border services, clinical supplies, pharmaceutical flows, international sponsor activity, and trade relationships.

Investment Intelligence

Identify high-growth CROs, emerging clinical research companies, trial technology providers, specialist sites, and investment opportunities.

Market Entry Strategy

Help international CROs, pharmaceutical companies, biotechnology firms, and healthcare technology providers evaluate Australia as an entry point into APAC.

GTM Strategy

Develop practical go-to-market strategies based on buyer segments, competitive gaps, therapeutic opportunities, geographic priorities, partnerships, and pricing dynamics.

Why Australia Matters to Global Clinical Development

Australia’s opportunity is bigger than its population.

Its strategic value comes from the combination of:

Regulatory infrastructure + clinical expertise + research institutions + early-phase capabilities + international sponsors + APAC connectivity.

The country’s clinical research ecosystem generated around AUD 1.6 billion in clinical-trial expenditure in 2022, supported approximately 90,000 trial participants, and continues to attract complex international studies.

At the same time, Towards Healthcare projects the Australian clinical research services market to grow from USD 2.00 billion in 2025 to USD 4.87 billion by 2035.

The next phase of growth will increasingly depend on specialization rather than scale alone.

CROs that can recruit difficult patient populations, accelerate first-in-human studies, manage complex modalities, support multinational APAC programs, and deliver reliable data will be better positioned to win sponsor business.

For investors and healthcare companies, the opportunity lies in identifying those capabilities before they become mainstream.

Frequently Asked Questions

What is the size of the Australia clinical research services market?

The Australia clinical research services market was valued at approximately USD 2.00 billion in 2025 and is projected to reach USD 4.87 billion by 2035, growing at a 9.3% CAGR from 2026 to 2035.

What is Australia’s clinical research services TAM?

Using the Towards Healthcare service-layer model, the broader Australian healthcare CRO opportunity was approximately USD 3.26 billion in 2025. This can be used as the broader TAM reference point for clinical research outsourcing.

What is the SAM for Australian clinical research support?

Clinical trial support services represented approximately USD 594.5 million in 2025, providing a useful SAM reference for outsourced clinical-trial execution services.

What is the major specialized opportunity within clinical research services?

Patient recruitment services were estimated at approximately USD 264.7 million in 2025 and represent a particularly important opportunity because recruitment delays directly affect trial timelines and sponsor costs.

How many clinical trials are conducted in Australia?

MTPConnect reported approximately 1,850 clinical trials commenced in Australia in 2022, with around 90,000 Australians participating.

Which companies are important in Australia’s clinical research ecosystem?

Important participants include Novotech, ICON, Avance Clinical, Scientia Clinical Research, and numerous global and specialist CROs, research sites, academic institutions, and technology providers.

Why is Australia attractive for Phase I clinical trials?

Australia combines established clinical infrastructure, experienced investigators, early-phase research capabilities, regulatory pathways, and access to international sponsors. Its role as a starting point for APAC development is also becoming increasingly important.

How can Towards Healthcare help companies entering Australia’s clinical research ecosystem?

Towards Healthcare Research & Consulting can support TAM/SAM/SOM analysis, buyer intelligence, CRO competitive benchmarking, clinical-trial intelligence, patient recruitment analysis, regulatory intelligence, import-export analysis, investment assessment, market-entry strategy, and go-to-market planning.